Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s share price hit a new 52-week low on Friday . The stock traded as low as C$1.69 and last traded at C$1.70, with a volume of 80251 shares trading hands. The stock had previously closed at C$1.75.
Cardiol Therapeutics Stock Performance
The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The company has a fifty day moving average of C$1.90 and a two-hundred day moving average of C$2.37. The stock has a market capitalization of C$143.55 million, a P/E ratio of -3.40 and a beta of 0.70.
Insider Buying and Selling at Cardiol Therapeutics
In related news, Senior Officer Guillermo Torre bought 17,240 shares of the firm's stock in a transaction on Thursday, December 26th. The stock was bought at an average cost of C$1.81 per share, for a total transaction of C$31,277.77. Also, Senior Officer Andrew Warwick Hamer bought 18,900 shares of the firm's stock in a transaction on Thursday, December 19th. The stock was bought at an average price of C$1.88 per share, with a total value of C$35,606.69. Insiders purchased a total of 86,140 shares of company stock worth $161,456 over the last ninety days. Company insiders own 4.57% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
